UP!

ACOR $0.62   View long term graphs

Acorda Therapeutics Inc.
Type
Public
Traded as NASDAQ: ACOR
S&P 600 Component
FWB: CDG
Industry Health care
Biotechnology
Founded 1995 (1995)
Founder Ron Cohen
Headquarters Ardsley, New York, United States
Key people
Ron Cohen (CEO)
Andrew R. Blight
Products Zanaflex
Ampyra
Qutenza
Revenue Increase US$292.2 Million (FY 2011)
Operating income
Increase US$35.1 Million (FY 2011)
Net income
Increase US$30.6 Million (FY 2011)
Total assets Increase US$379.5 Million (FY 2011)
Total equity Increase US$205.2 Million (FY 2011)
Number of employees
328 (February, 2012)
Website Acorda.com

Acorda Therapeutics is a biotechnology company based in Ardsley, New York, USA. The company develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda manufactures and markets the drugs Zanaflex, Ampyra and Qutenza in the United States.

In September 2014 the company acquired Civitas Therapeutics for $525 million - gaining the Phase III Parkinson’s drug, CVT-301.

In January 2016, the company acquired Finnish pharmaceutical company, Biotie Therapies, for $363 million. This gave the company control over Biotes sclerosing cholangitis drug, BTT1023.

In November 2016, Acorda Therapeutics announced it was discontinuing development of dalfampridine, a drug intended for post-stroke walking difficulties, after a clinical trial failure. The discontinuation of the drug caused Acorda's shares to drop as much as 13.2%. Acorda shares have dropped 50.2% since January 2016.

As of November 5, 2017, the members of the board of directors of Acorda Therapeutics were: Ron Cohen, Barry Greene, Peder K. Jensen, John P. Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, Ian F. Smith, and Catherine Strader.

News

Acorda Therapeutics, Inc. 30.13% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2020 2020-10-21 Future report Set alerts
Q2 2020 2020-08-04 0.00 0.00
Q1 2020 2020-05-05 -0.51 -0.14
Q4 2019 2020-02-13 -0.15 1.38
Q3 2019 2019-11-04 -0.46 -5.55
Q2 2019 2019-08-01 -0.55 -0.58
Q1 2019 2019-05-02 -0.56 -1.00
Q4 2018 2019-02-14 0.45 0.20
Q3 2018 2018-10-31 0.17 -0.29
Q2 2018 2018-08-02 1.40 0.98

Ratings

2016-06-01 Boost Price Target Aegis Buy $40.00 to $52.00
2016-05-22 Reiterated Rating Leerink Swann Hold $31.00 to $29.00
2016-05-20 Reiterated Rating Cowen and Company Outperform $65.00 to $60.00
2016-05-20 Reiterated Rating Evercore ISI Hold $32.00
2016-04-28 Reiterated Rating Cowen and Company Buy
2016-04-17 Reiterated Rating Cowen and Company Buy
2016-03-30 Initiated Coverage Goldman Sachs Sell $23.00
2016-03-30 Initiated Coverage Goldman Sachs Group Inc. Sell $23.00
2016-03-14 Lower Price Target Stifel Nicolaus Buy $48.00
2016-02-12 Reiterated Rating Stifel Nicolaus Buy $53.00
2016-01-19 Reiterated Rating Leerink Swann Market Perform $35.00
2016-01-13 Reiterated Rating Cowen and Company Outperform $65.00
2016-01-11 Reiterated Rating JPMorgan Chase & Co. Neutral
2016-01-06 Boost Price Target Aegis Buy $40.00 to $52.00
2015-10-23 Reiterated Rating Aegis Buy $40.00
2015-10-22 Reiterated Rating JPMorgan Chase & Co. Hold $42.00
2015-10-05 Reiterated Rating Leerink Swann Hold
2015-10-05 Reiterated Rating Cowen and Company Buy $65.00
2015-09-01 Initiated Coverage Aegis Buy $40.00
2015-08-31 Initiated Coverage Raymond James Market Perform
2015-08-31 Initiated Coverage Raymond James Financial Inc. Market Perform
2015-08-25 Reiterated Rating Stifel Nicolaus Buy $47.00
2015-08-25 Reiterated Rating Cowen and Company Outperform $65.00
2015-08-25 Reiterated Rating JPMorgan Chase & Co. Neutral
2015-07-31 Reiterated Rating Canaccord Genuity Hold $32.00
2015-07-31 Reiterated Rating JPMorgan Chase & Co. Neutral $42.00
2015-07-30 Reiterated Rating Cowen and Company Outperform $65.00
2015-06-22 Set Price Target MLV & Co. Buy $58.00
2015-06-09 Initiated Coverage Guggenheim Neutral
2015-05-27 Reiterated Rating Canaccord Genuity Hold $30.00
2015-05-15 Reiterated Rating Canaccord Genuity Hold $30.00
2015-05-01 Reiterated Rating JPMorgan Chase & Co. Neutral $42.00
2015-05-01 Reiterated Rating Canaccord Genuity Hold $30.00
2015-04-22 Initiated Coverage Piper Jaffray Neutral
2015-04-22 Initiated Coverage Piper Jaffray Cos. Neutral
2015-02-15 Reiterated Rating JPMorgan Chase & Co. Neutral $42.00
2015-02-15 Reiterated Rating Canaccord Genuity Hold $30.00
2015-02-13 Reiterated Rating Citigroup Inc. Hold $46.00 to $42.00
2015-02-12 Initiated Coverage MLV & Co. Buy $58.00
2015-02-11 Set Price Target RBC Capital Buy $45.00
2015-02-11 Set Price Target Royal Bank Of Canada Buy $45.00
2015-01-13 Reiterated Rating Citigroup Inc. Hold $36.00 to $46.00
2015-01-12 Reiterated Rating JPMorgan Chase & Co. Neutral
2015-01-05 Set Price Target JPMorgan Chase & Co. Hold $42.00
2014-12-26 Reiterated Rating Aegis Buy
2014-12-04 Initiated Coverage Goldman Sachs Neutral $40.00
2014-10-31 Reiterated Rating FBR & Co. Outperform $57.00 to $59.00
2014-10-31 Reiterated Rating Citigroup Inc. Neutral $34.00 to $36.00
2014-10-31 Reiterated Rating FBR & Co Outperform $57.00 to $59.00
2014-10-30 Boost Price Target MKM Partners Neutral $31.50 to $33.00
2014-08-19 Resumed Stifel Buy $47
2014-08-19 Initiated Coverage Stifel Nicolaus Buy $47.00
2014-05-07 Lower Price Target MKM Partners Neutral $33.00 to $31.50
2014-05-06 Reiterated Rating Aegis Buy
2014-05-05 Reiterated Rating Citigroup Inc. Hold $34.00
2014-04-21 Upgrade Ned Davis Research Sell to Neutral
2014-04-17 Initiated Coverage Canaccord Genuity Hold $37.00
2014-04-14 Upgrade FBR Capital Mkt Perform to Outperform $30 to $47
2014-04-14 Upgrade FBR & Co. Market Perform to Outperform $30.00 to $47.00
2014-01-06 Downgrade Citigroup Inc. Buy to Neutral $37.00 to $33.00
2013-11-01 Upgrade MKM Partners Sell to Neutral $33.00 to $32.00
2013-11-01 Reiterated FBR Capital Outperform $35 to $30
2013-11-01 Lower Price Target FBR & Co. Outperform $35.00 to $30.00
2013-10-30 Initiated FBR Capital Mkt Perform $35
2013-10-30 Initiated Coverage FBR & Co. Market Perform $35.00
2013-10-01 Reiterated Aegis Capital Buy $43 to $50
2013-10-01 Boost Price Target Aegis Buy $43.00 to $50.00
2013-08-01 Reiterated Feltl & Co. Buy $40 to $43
2013-05-02 Downgrade MKM Partners Neutral to Sell
2013-04-16 Reiterated MKM Partners Neutral $31 to $33
2013-04-15 Reiterated Aegis Capital Buy $34 to $40
2013-01-08 Downgrade MKM Partners Buy to Neutral
2012-03-15 Resumed Stifel Nicolaus Buy $34
2012-01-09 Upgrade MKM Partners Neutral to Buy $26 to $32
2011-09-20 Initiated MKM Partners Neutral $25
2011-04-20 Reiterated RBC Capital Mkts Outperform $32 to $38
2010-12-14 Downgrade Robert W. Baird Outperform to Neutral $40 to $31
2010-09-09 Initiated Stifel Nicolaus Buy $39
2010-09-07 Upgrade Robert W. Baird Neutral to Outperform $40
2010-04-15 Reiterated RBC Capital Mkts Outperform $36 to $40
2010-03-29 Initiated Citigroup Hold
2010-02-17 Reiterated RBC Capital Mkts Outperform $30 to $36
2010-02-04 Downgrade Robert W. Baird Outperform to Neutral $32
2016-06-01 Boost Price Target Aegis Buy $40.00 to $52.00
2016-05-22 Reiterated Rating Leerink Swann Hold $31.00 to $29.00
2016-05-20 Reiterated Rating Cowen and Company Outperform $65.00 to $60.00
2016-05-20 Reiterated Rating Evercore ISI Hold $32.00
2016-04-28 Reiterated Rating Cowen and Company Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
SCOPIA FUND MANAGEMENT, LLC 20.30%  (8474728) ACOR / ITRI / PHH /
COHEN RON President and CEO 1.35%  (564285) ACOR / DYAX /
Wasman Jane Exec VP, General Counsel & Sec 0.26%  (106809) ACOR / GALE /
Blight Andrew Chief Scientifc Officer 0.19%  (78594) ACOR /
Batycky Richard P. Chief Tech. Off. & Site Head 0.13%  (55513) ACOR /
Hindman Andrew A. Chief Business Dev. Officer 0.12%  (51048) ACOR /
ROGERS MICHAEL W Chief Financial Officer 0.10%  (40713) ACOR / BGMD / CNDO / KERX / PSDV /
Wessel Thomas Chief Medical Officer 0.09%  (36350) ACOR /
BLANK BURKHARD Chief Medical Officer 0.08%  (33150) ACOR /
Carrazana Enrique J. Chief Medical Officer 0.08%  (32148) ACOR / MRNS /
Sabella Lauren M Exec. VP-Commercial Dvlpmnt 0.04%  (18453) ACOR /
LAWRENCE DAVID Chief Financial Officer 0.02%  (8124) ACOR /
PANEM SANDRA PHD 0.01%  (2912) ACOR /

Comments